Taken together, this suggests that disrupting the SP-A:MYADM axis leads to not only an increase and persistence in key phenotypes associated with inflammation (i.e., persistent eosinophilia and mucus), but also a delay in the resolution of constricted airways and airways resistance that is associated with asthma. This evidence concerns the gene MYADM and asthma.